Neal McGarry, PA
Medical · Glendale, AZNPI 1962830638
Payments from drug & device makers
Across 301 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$991
- Novo Nordisk$645
- Lilly USA, LLC$624
- Novartis$250
- BETA Bionics, Inc.$206
- Boehringer Ingelheim$172
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,25097%
- Education$1513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $991 |
| Novo Nordisk | 68 | $645 |
| Lilly USA, LLC | 44 | $624 |
| Novartis | 10 | $250 |
| BETA Bionics, Inc. | 13 | $206 |
| Boehringer Ingelheim | 10 | $172 |
| Dexcom, Inc. | 9 | $148 |
| Insulet Corporation | 7 | $144 |
| AstraZeneca(2 entities) | 7 | $124 |
| Tandem Diabetes Care, Inc. | 5 | $98 |
| Radius Health, Inc. | 5 | $95 |
| Chiesi USA, Inc. | 4 | $92 |
| Amgen(2 entities) | 5 | $91 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Sanofi-aventis U.S. LLC | 3 | $82 |
| Neurocrine Biosciences, Inc. | 2 | $66 |
| Amryt Pharma Holdings Ltd | 3 | $54 |
| Recordati_rare_diseases_inc. | 3 | $53 |
| Medtronic | 3 | $48 |
| Bayer | 3 | $42 |
| Sequel Med Tech, LLC | 1 | $38 |
| IBSA Pharma Inc. | 2 | $35 |
| AbbVie | 2 | $34 |
| Corcept Therapeutics | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Pfizer | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
How this compares
$4,402 in reported general payments places this provider in the 80th percentile of 748 medical providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 386 | $430,339 |
| OzempicSemaglutide | 207 | $301,878 |
| JardianceEmpagliflozin | 148 | $168,691 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 123 | $138,582 |
| TrulicityDulaglutide | 74 | $90,551 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 96 | $58,152 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $54,513 |
| TradjentaLinagliptin | 43 | $43,760 |
| FarxigaDapagliflozin Propanediol | 36 | $43,727 |
| Novolog FlexpenInsulin Aspart | 141 | $39,308 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $33,624 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $28,582 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 219 | $27,997 |
| JanuviaSitagliptin Phosphate | 27 | $27,957 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $24,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $624 | $529,968495 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $645 | $339,329269 claims |
| Boehringer IngelheimJardiance, Tradjenta | $172 | $212,452191 claims |
| AstraZenecaFarxiga | $124 | $43,72736 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog, Lantus | $82 | $21,68143 claims |
| AbbVieSynthroid | $34 | $2,24521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 748 medical providers in Arizona.
Other medical in Glendale
- Kaitlyn HasanGlendale$16K
- Molly MoloznikGlendale$9K
- David BeckGlendale$8K
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Linda MoorsTucson$122K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.